University Hospital Basel, Division of Outpatient Cardiology
Basel, 4031, Switzerland
Location status: Recruiting
Location contact
Otmar Pfister, Prof. Dr. med.
CONTACT
Otmar Pfister, Prof. Dr. med.
PRINCIPAL_INVESTIGATOR
NCT Number: NCT05500859
The SwissPR study is to continuously monitor patient characteristics and short- and long-term benchmark quality measures and outcomes of patients participating in a 12-week ambulatory CR program.
Interested in participating?
Request InfoAll sexes
Observational
Basel, 4031, Switzerland
Location status: Recruiting
Otmar Pfister, Prof. Dr. med.
CONTACT
Otmar Pfister, Prof. Dr. med.
PRINCIPAL_INVESTIGATOR
The SwissPR study is a non-interventional, longitudinal observational cohort study consisting of a retrospective and a prospective part of patients who have completed the Cardiac Rehabilitation (CR) program of the University Hospital Basel. Assessing the impact of a CR program on key cardiovascular Benchmark Performance Measures (BPM) and its persistence over time would be helpful on internal quality control as well as identification of special need patients with highest cardiovascular risk. "KARAMBA" is the outpatient cardiovascular prevention and rehabilitation program of the University Hospital Basel (USB) and is one of the largest CR centers in Switzerland. Data regarding the Swiss population during and after CR is missing so far, thus creating a Swiss Prevention and Rehabilitation Registry (= SwissPR) on the basis of the KARAMBA infrastructure has the potential to collect missing data and address these questions. The results of the study will identify patient profiles at increased risk (special need patients) and will shed light into the mechanisms of poor secondary prevention behavior. The objective of SwissPR is to continuously monitor patient characteristics and short- and long-term benchmark quality measures and outcomes of patients participating in a 12-week ambulatory CR program.
For the prospective and retrospective part no recruitment or screening procedure is required. The procedure of enrolling patients for the prospective cohort of SwissPR patients is based on the participation in the CR program of the University Hospital Basel. Patients are routinely referred by various institutions for participation in the CR program according to predefined cardiovascular diagnosis. The retrospective part applies to data of patients, which have completed the CR program in Basel between 2017 and 2019.
Procedures:
Visit 1: Baseline, start of ambulatory CR program (approx. 60min): Patient characteristics including medical history, current medication, cardiovascular risk factors, routine laboratory analysis (including lipids, Hb1c, NT-proBNP), clinical status, electrocardiogram, echocardiography data from latest echo, cardio pulmonary exercise testing (CPET), questions on general health behavior (diet, weekly exercise load), Quality of Life and questions on socio-economic parameters.
Visit 2: End of CR program, 3 months after baseline (approx. 60 min.): Same measurements and procedures as at visit 1.
Visit 3: 1-year follow-up (approx. 15 min.): Same measurements and procedures as at visit 1 and 2 except for CPET.
Telephone follow-up and questionnaire 3 years after CR (approx. 15 min.): After checking vital status, the following end-points and information will be collected by telephone interview: hospitalisations since last follow-up (cardiac, non-cardiac), Major Cardiovascular Adverse Events (MACE) including cardiovascular mortality, myocardial infarction, stroke, revascularization, hospitalization for heart failure, smoking status and physical activity. The questionnaire contains questions on health behaviour, quality of life, depression and medication.
Telephone follow-up and questionnaire 5 years after CR (approx. 15 min.): Same interview and questionnaire as at 3-year follow-up.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Data collection (Patient characteristics including medical history, current medication, cardiovascular risk factors, routine laboratory analysis (including lipids, Hb1c, NT-proBNP), clinical status, electrocardiogram, echocardiography data from latest echo, cardio pulmonary exercise testing (CPET), questions on general health behavior (diet, weekly exercise load), Quality of Life and questions on socio-economic parameters)
Time frame: 1 year
Change in Guideline recommended medical therapy (Guideline recommended medical therapy is one variable in predefined secondary prevention benchmark performance measures (BPM) at one year after CR)
Time frame: 1 year
Change in predefined secondary prevention benchmark performance measures (BPM) at one year after CR: LDL-Cholesterol target value
Time frame: 1 year
Change in predefined secondary prevention benchmark performance measures (BPM) at one year after CR: Achievement of target blood-pressure
Time frame: 1 year
Change in smoking status (smoking status is a predefined secondary prevention benchmark performance measures (BPM) at one year after CR: Achievement of Non-smoking status)
Time frame: 1 year
Change in predefined secondary prevention benchmark performance measures (BPM) at one year after CR: Achievement of 150 minutes of exercise/ week (self-reported)
Time frame: 3 months after baseline
Percentage of patients reaching the predefined secondary prevention benchmark after CR
Time frame: up to 5 years
Change in physical activity (measured by exercise capacity (Watt) since last follow-up
Time frame: up to 5 years
Change in medical therapy between visits
Time frame: up to 5 years
Change in quality of life questionnaire between visits. The questionnaire covers various attributes of an individuals life, summing the items for each life area for a total score (possible score range 0-96).
Time frame: up to 5 years
Change in Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention (TRS 2P): 3 categories: G1 (Low-risk; TRS-2P = 0/1); G2 (Intermediate-risk; TRS-2P = 2); and, G3 (High-risk; TRS-2P ≥ 3)
Time frame: up to 5 years
Number of total mortality after 1, 3 and 5 years
Time frame: up to 5 years
Change in total MACE after 1, 3 and 5 years
Contact information is provided by the study sponsor or research team.
Otmar Pfister, Prof. Dr. med.
CONTACT
Steffen Biniasch
CONTACT
University Hospital, Basel, Switzerland
Other
Swiss Secondary Prevention and Rehabilitation Registry: SwissPR
Acronym: SwissPR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07401550
Arterial Occlusive Diseases, Arteriosclerosis
Dublin, Ireland
View Trial DetailsNCT07724522
Body Weight, Cardiovascular Diseases
Washington D.C., District of Columbia, United States
View Trial DetailsNCT07704164
Arterial Occlusive Diseases, Arteriosclerosis
Barcelona, Spain
View Trial DetailsNCT07483502
Cardiovascular Diseases, Cardiovascular Diseases (CVD)
Hull, East Riding Of Yorkshire, United Kingdom
View Trial Details